Free Submission Public Relations &
Deutsch English

Point of Care Coagulation Testing: World Market 2013-2023

Global point of care diagnostics market: $14 billion industry in 2011

Print article Print article
2014-02-24 10:55:03 - Point of Care Coagulation Testing: World Market 2013-2023 - a new market research report on

In 2011, the global point of care diagnostics market was worth $13.8bn, with high single-digit growth from the year before. Despite being a vast and mature market, there are number of sectors likely to experience fast growth during the next 10 years. Much of this growth is linked to the prevalence of a number of diseases worldwide, as well as an aging population. The preference for at home testing and its convenience will continue to drive the point of care diagnostics market.

The point of care coagulation market is one of the largest sectors in the global point of care industry. In 2011, the global POC coagulation testing market (including the sales of kits and instruments) was valued at $1.0bn. Total



sales in this market are predicted to reach $1.8bn in 2017. PT/INR testing was the largest segment in the POC coagulation testing market with sales of $0.6bn in 2011.

For the past several years, four companies - Roche, International Technidyne Corporation (ITC), Abbott, and Alere - have dominated the POC PT/INR testing market. The devices currently available in the market are able to meet demand. However, there is need for improvement in technology to attract more physicians and patients to use this testing. Most of the testing for patients on anticoagulant warfarin is currently conducted in laboratories. Such patients need regular monitoring. The use of POC tests can help save a lot of time and money spent on unwanted complications arising from the use of the drug without monitoring.

The primary driver for growth will be the increasing use of anticoagulant therapy and higher adoption of self-testing kits for use at home. Anticoagulant drugs are commonly used for the treatment of thrombosis and associated disorders, including stroke, myocardial infarction and pulmonary embolism. The global epidemic of heart attack and stroke is predicted to continue and indeed worsen, from 2011 to 2023. However, market growth will slow down beyond 2017, with the launch of new oral anticoagulants in the market to replace warfarin.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Mike King
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact